



PRESS RELEASE

Published: 22-05-2023

Inhalation Sciences receives new order worth 53,000 Euro from returning customer

Inhalation Sciences AB (ISAB) has received a new order worth 53,000 Euro from a regular client – a large global player in the field of inhaled therapies with a strong development pipeline based in Europe. The order is for additional modules and accessories that will expand the client's two existing PreciseInhale systems.

The client is a loyal ISAB customer, with two PreciseInhale systems in place. The client's team carry out advanced *in vivo* work on New Chemical Entities, using the highly accurate preclinical data generated by PreciseInhale to significantly reduce risk in the later clinical stages of development of its inhaled therapies.

Predicting and preventing failure at the preclinical stage, a relatively inexpensive stage of drug development, can produce enormous savings for companies in a market where the cost of developing drugs can easily run into billions of dollars (a 2020 study estimated the average cost of getting a new drug into the market to be 1.3 BUSD ¹).

CEO Manoush Masarrat: "This new order speaks to the great value our technology delivers to customers and how that value can keep growing with the system. PreciseInhale is a truly flexible, multi-modular system that can deliver highly accurate data across a range of *in vitro* and *in vivo* exposure modules, sourced from dry powder, inhaled or nebulized aerosols. We are pleased to see the great value PreciseInhale continues to deliver to our client."

1. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7054832/>

For more information about Inhalation Sciences, please contact:

Manoush Masarrat, CEO

E-mail: Manoush.masarrat@inhalation.se

Mobile: +46 (0)73 628 9153

About Inhalations Sciences Sweden AB (publ)

Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments and services for research into inhalation. The company's patented lab instruments PreciseInhale® and DissolvIt® enable researchers in the pharma industry to make drug pipeline decisions at an early stage, saving time and resources for R&D departments, and enables researchers in academic institutions to define how aerosols and small particles impact our lungs, and so our health, when being inhaled.

The information above was provided by Inhalation Sciences Sweden AB according to EU Market Abuse Regulations. The information was provided, through the above contact person, for publication on 22 May 2023.